These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34588773)

  • 21. The COPD Assessment Test (CAT) can screen for fatigue among patients with COPD.
    Stridsman C; Svensson M; Johansson Strandkvist V; Hedman L; Backman H; Lindberg A
    Ther Adv Respir Dis; 2018; 12():1753466618787380. PubMed ID: 30035671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Values of Body Mass Index and Chest CT Features in the Assessment of Chronic Obstructive Pulmonary Disease].
    Li L; Liu Y; Li J; Gao JM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Feb; 42(1):55-61. PubMed ID: 32131940
    [No Abstract]   [Full Text] [Related]  

  • 23. Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations.
    Jones PW; Nadeau G; Small M; Adamek L
    Respir Med; 2014 Jan; 108(1):129-35. PubMed ID: 24041746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of symptom and risk assessment methods among patients with chronic obstructive pulmonary disease.
    Zhang R; Tan X; He Q; Chen Q; Gai J; Wei J; Wang Y
    Chin Med J (Engl); 2014; 127(14):2594-8. PubMed ID: 25043073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study.
    Exuzides A; Colby C; Briggs AH; Lomas DA; Rutten-van Mölken MPMH; Tabberer M; Chambers M; Muellerova H; Locantore N; Risebrough NA; Ismaila AS; Gonzalez-McQuire S
    Med Decis Making; 2017 May; 37(4):453-468. PubMed ID: 26449490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD).
    Rebordosa C; Plana E; Aguado J; Thomas S; García-Gil E; Perez-Gutthann S; Castellsague J
    Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):126-133. PubMed ID: 29740896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mini Nutritional Assessment Short-Form predicts exacerbation frequency in patients with chronic obstructive pulmonary disease.
    Yoshikawa M; Fujita Y; Yamamoto Y; Yamauchi M; Tomoda K; Koyama N; Kimura H
    Respirology; 2014 Nov; 19(8):1198-203. PubMed ID: 25208631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
    Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COPD Assessment Test Changes from Baseline Correlate with COPD Exacerbations: A Longitudinal Analysis of the DACCORD Observational Study.
    Kardos P; Vogelmeier CF; Worth H; Buhl R; Obermoser V; Criée CP
    Lung; 2020 Jun; 198(3):507-514. PubMed ID: 32367415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Previous Pulmonary Tuberculosis on Chronic Obstructive Pulmonary Disease: Baseline Results from a Prospective Cohort Study.
    Wang Y; Li Z; Li F
    Comb Chem High Throughput Screen; 2023; 26(1):93-102. PubMed ID: 35388750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease.
    Dransfield MT; Kunisaki KM; Strand MJ; Anzueto A; Bhatt SP; Bowler RP; Criner GJ; Curtis JL; Hanania NA; Nath H; Putcha N; Roark SE; Wan ES; Washko GR; Wells JM; Wendt CH; Make BJ;
    Am J Respir Crit Care Med; 2017 Feb; 195(3):324-330. PubMed ID: 27556408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease.
    Fortis S; Comellas A; Make BJ; Hersh CP; Bodduluri S; Georgopoulos D; Kim V; Criner GJ; Dransfield MT; Bhatt SP;
    Ann Am Thorac Soc; 2019 Jul; 16(7):826-835. PubMed ID: 30908927
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
    Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of the CAT in the therapy assessment of COPD exacerbations in China.
    Tu YH; Zhang Y; Fei GH
    BMC Pulm Med; 2014 Mar; 14():42. PubMed ID: 24618290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of Luminal Mucus Score in Large Airways with Lung Function and Quality of Life in Severe Acute Exacerbation of COPD: A Cross-Sectional Study.
    Yang C; Zeng HH; Du YJ; Huang J; Zhang QY; Lin K
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1449-1459. PubMed ID: 34093010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fixed-dose combination of three drugs, i.e. LABA/LAMA/ICS for COPD: Results of a real-world study from India.
    Salvi S; Deb AK; Agarwal M; Tummuru VR; Kodgule R; Hemalatha VS; Awasthi AK; Suraj KP; Pavitran VK; Mourya SP; Thomas P; Vaidya A; Chhowala S; Gogtay J
    Pulm Pharmacol Ther; 2020 Aug; 63():101932. PubMed ID: 32777289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Relationship Between Clinical Phenotypes and Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stages/Groups in Patients With Chronic Obstructive Pulmonary Disease.
    Pandey AK; Verma AK; Singh A; Kant S; Dixit RK; Chaudhary SC; Bajpai J; Prakash V; Verma UP
    Cureus; 2022 Dec; 14(12):e32116. PubMed ID: 36601200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A two-year evaluation of the 'real life' impact of COPD on patients in Germany: The DACCORD observational study.
    Kardos P; Vogelmeier C; Worth H; Buhl R; Lossi NS; Mailänder C; Criée CP
    Respir Med; 2017 Mar; 124():57-64. PubMed ID: 28284322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients.
    Song Q; Zhao YY; Zeng YQ; Liu C; Cheng W; Deng MH; Li X; Ma LB; Chen Y; Cai S; Chen P
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1401-1412. PubMed ID: 34040367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.